Arecor Reveals Co-Development Partnership with US Insulin Pump Firm for AT278, Along with Sale of Royalty Rights and Technology Access Fees for AT220 and AT292
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 24 2025
0mins
Source: Globenewswire
Co-Development Agreement: Arecor Therapeutics has entered a co-development agreement with Sequel Med Tech to advance AT278, an ultra-concentrated insulin, in conjunction with Sequel's automated insulin delivery system, aiming for a pivotal Phase 2 trial by 2026.
Funding and Financial Strategy: Arecor has secured up to $11 million through a royalty financing agreement with Ligand Pharmaceuticals, extending its cash runway to the first half of 2027 and allowing for accelerated development of AT278 without shareholder dilution.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
